Service by

Home Journal Issues Guide for Authors Editorial Board About Journal Aims & Scope


Open Access

Review Article



MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH

Russel J REITER*; Fatih GULTEKIN; Luis J FLORES; Ma Pilar TERRON; Dun-Xian TAN.

Cited by (17)

Abstract
This review summarizes the beneficial actions of melatonin in various experimental conditions/diseases and identifies where the use of melatonin may be helpful in improving public health. The nightly use of melatonin supplements by humans often improves their sleep and helps correct the circadian dyssynchronization associated with “jet lag”. Additionally, melatonin has been found effective in curtailing the growth of a variety of experimental cancers. Mechanistically, this is achieved by melatonin’s ability to limit fatty acid uptake, especially linoleic acid, by tumor cells. Fatty acids are growth factors for many tumors. Additionally, melatonin inhibits the elevated telomerase activity of tumor cells thus making them more fragile and vulnerable to chemotherapies. Melatonin also may inhibit angiogenesis in tumors by suppressing endothelin-1 production and the indole interferes with the stimulatory action of steroids on hormone-responsive tumors. As an ubiquitously-acting antioxidant, melatonin reduces cardiac damage during ischemia/reperfusion (I/R) injury (heart attack) and during I/R to the brain (stroke). Melatonin also limits the toxicity of amyloid  peptide and of neurofibrillary tangles, two of the cardinal signs of Alzheimer’s disease. Collectively, these data suggest supplementation with melatonin, whose endogenous levels decrease with age, may improve the quality of life in the aged and, as a consequence, be beneficial for public health generally.

Key words: Melatonin, free radical scavenger, antioxidant, ischemia/reperfusion, cancer, Alzheimer disease, sleep, jet lag



MELATONN: TOPLUM SALIINI GELTRMEK N POTANSYEL KULLANIMI

Özet
Bu derleme melatoninin eitli deneysel durum/hastalktaki faydal etkilerini zetlemekte ve melatoninin toplum saln gelitirmede faydal olabilecek kullanm alanlarn belirlemektedir. Melatoninin gecelik kullanm sklkla uyku kalitesini arttrmakta ve “jet lag”la ilikili sirkadiyan senkronizasyon bozukluunu dzeltmeye yardmc olmaktadr. lave olarak melatoninin eitli deneysel kanserlerin bymesini yavalatmada etkili olduu bulunmutur. Bu; melatoninin tmr hcreleri tarafndan ya asitlerini, zellikle de linoleik asitin, almn snrlamasyla baarlmaktadr. Ya asitleri bir ok tmr iin byme faktrdr. Buna ilave olarak, melatonin tmr hcrelerinin artm telomeraz aktivitelerini inhibe etmekte ve dolays ile bu hcreleri daha frajil ve kemoterapilere kar daha duyarl hale getirmektedir. Melatonin ayn zamanda endotelin-1 retimini ve hormon-baml tmrlerdeki steroidlerin stimlatuvar etkilerini engelleyen indol basklayarak tmrlerdeki anjiogenezisi inhibe edebilir. Esiz bir antioksidan olarak melatonin, iskemi/reperfzyon (I/R) bozukluunda (kalp krizi) meydana gelen kardiyak hasar ve beyin I/R bozukluundaki (inme) beyin hasarn azaltr. Melatonin ayrca Alzheimer hastalnn iki temel bulgusu olan amiloid  peptid ve nrofibrular dm toksititesini snrlar. Ksacas bu veriler, endojen dzeyleri yala azalan, melatonin takviyesinin yallkta yaam kalitesini arttrabileceini ve sonuta tm toplum sal iin genel olarak faydal olabileceini desteklemektedir.

Anahtar Kelimeler: Melatonin, serbest radikal toplayc, antioksidan, iskemi/reperfzyon, kanser, Alzheimer hastal, uyku, jet lag


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Russel J REITER*; Fatih GULTEKIN; Luis J FLORES; Ma Pilar TERRON; Dun-Xian TAN
on Google
on Google Scholar
Article Statistics
 Viewed: 18420
Downloaded: 1430
Cited: 17


REFERENCES
1. Pappolla MA, Chyan YJ, Poeggeler B, Frangione R, Wilson G et al. An assessment of the antioxidant and antiamyloidogenic properties of melatonin: implications for Alzheimer’s disease. J Neural Transm. 2000; 107:203-31. [DOI via Crossref]    [Pubmed]   
2. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S et al. Effects of melatonin treatment on septic newborns. Pediatr Res. 2001; 50:756-60. [DOI via Crossref]    [Pubmed]   
3. Herrera J, Nava M, Romero F, Rodríguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis. 2001; 37:750-7. [DOI via Crossref]   
4. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Topics Med Chem 2002; 2:113-33. [DOI via Crossref]   
5. Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer 2002; 10:110-6. [DOI via Crossref]    [Pubmed]   
6. Todisco M, Casaccia P, Rossi N. Severe bleeding symptom’s in refractory idiopathic thrombocytopenia purpura: a case successfully treated with melatonin. Am J Therap. 2003; 10:135-6. [DOI via Crossref]   
7. Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chuirazzi P et al. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm infants. Am J Perinotol. 2004; 21:209-16. [DOI via Crossref]    [Pubmed]   
8. Reiter RJ, Tan DX, Pappaolla MA. Melatonin relieves the neural oxidative burden that contributes to dementias. Ann NY Acad Sci. 2004; 1035: 179-86. [DOI via Crossref]    [Pubmed]   
9. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005; 6:459-66. [DOI via Crossref]    [Pubmed]   
10. Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E. When melatonin gets on your nerves: Its beneficial actions in experimental models of stroke. Exp Biol Med. 2005; 230:104-17.
11. Reiter RJ. The pineal and its hormones in the control of reproduction in mammals. Endocr Rev. 1980; 1:109-31. [DOI via Crossref]    [Pubmed]   
12. Lewy AJ. Melatonin as a marker and phase-resetter of circadian rhythms in humans. Adv Exp Med Biol. 1999; 460:425-34. [DOI via Crossref]    [Pubmed]   
13. Skinner DC, Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Golen vein blood recirculating through the choroid plexus. Endocrinology. 1999; 140-4399-405.
14. Reiter RJ. Melatonin: the chemical expression of darkness. Molec Cell Endocrinol. 1991; 79:C153-9. [DOI via Crossref]   
15. Pang SF, Allen AE. Extra-pineal melatonin in the retina: its regulation and physiological function. Pineal Res Rev. 1986; 4:55-96.
16. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J. 2005; 19:176-94. [DOI via Crossref]    [Pubmed]   
17. Bubenik GA. Gastrointestinal melatonin: localization, function and clinical relevance. Dig Dis Sci. 2002; 47:2336-48. [DOI via Crossref]    [Pubmed]   
18. Conti A, Conconi S, Hertens S, Skwarlo-Sonta K, Markowska M et al. Evidence of melatonin synthesis in mouse and human bone marrow cells. J Pineal Res. 2000; 28:193-202. [DOI via Crossref]    [Pubmed]   
19. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role in intracrine, autocrine, and/or paracrine substance. FASEB J. 2004; 18:537-9. [Pubmed]   
20. Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003; 34:75-8. [DOI via Crossref]    [Pubmed]   
21. Reiter RJ, Richardson BA, Johnson LY, Ferguson BN, Dinh DT. Pineal melatonin rhythm: reduction in aging Syrian hamster. Science 1980; 210:1372-3. [DOI via Crossref]    [Pubmed]   
22. Reiter RJ, Craft CM, Johnson JE Jr., King TS, Richardson BA, et al. Age-associated reduction in nocturnal melatonin levels in female rats. Endocrinology. 1981; 109:1295-7. [DOI via Crossref]    [Pubmed]   
23. Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM. Human melatonin production decreases with age. J Pineal Res. 1986; 3:479-88. [DOI via Crossref]   
24. Skene DJ, Vivien-Roels B, Sparks DL, Hunsaker JC, Pevet P et al. Daily variation of the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer’s disease. Brain Res. 1990; 528:170-4. [DOI via Crossref]   
25. Poeggeler B. Melatonin, aging, and related diseases. Endocrine. 2005; 27:201-12. [DOI via Crossref]   
26. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science. 1980; 210:1267-9. [DOI via Crossref]    [Pubmed]   
27. Brainard GC, Rollag MD, Hanifin JP. Photic regulation of melatonin in humans: ocular and neural signal transduction. J Biol Rhythms 1997; 12:537-46. [DOI via Crossref]    [Pubmed]   
28. Wehr TA. The durations of human melatonin secretion and sleep response to changes in daylength. J Clin Endocrinol Metab. 1991; 73:1276-80. [DOI via Crossref]    [Pubmed]   
29. Erren TC, Reiter RJ, Piekarski C. Light, timing of biological rhythms, and chronodisruption in man. Naturwissenschaften 2003; 90:485-95. [DOI via Crossref]    [Pubmed]   
30. Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci. 2001; 21:6405-12. [Pubmed]   
31. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Dev. 1991; 12:151-80. [DOI via Crossref]    [Pubmed]   
32. James SP, Sack DA, Rosenthal NE, Mandelson WB. Melatonin administration in insomnia. Neuropsychopharmacology. 1990; 3:19-23. [Pubmed]   
33. Oldani A, Ferini-Strambi L, Zacconi M, Stankov B, Fraschini F et al. Melatonin and delayed sleep phase syndrome: ambulatory polygraphic evaluation. Neuroreport. 1994; 30:132-4. [DOI via Crossref]   
34. Skene DJ, Lockley SW, Arendt J. Use of melatonin in treatment of phase shift and sleep disorders. Adv Exp Med Biol. 1999; 467:79-84. [DOI via Crossref]    [Pubmed]   
35. Herxheimer A. Does melatonin help people sleep? BMJ 2006; 332:373-4. [DOI via Crossref]    [PMC Free Fulltext]   
36. Buscerni N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders accompanying sleep restriction: meta-analysis. BMJ [DOI via Crossref]    [DOI via Crossref]   
37. Wirz-Justice A, Armstrong SM. Melatonin: nature’s soporific? J Sleep Res. 1996; 5:13-41.
38. Pandi-Perumal SR, Zisapel N, Srinivasan, Cardinali DP. Melatonin and sleep in an aging population. Exp Gerontol. 2005; 40:911-25. [DOI via Crossref]    [Pubmed]   
39. Baskett JJ, Broad JB, Word PC, Duncan JR, Pledger MJ, et al. Does melatonin improve sleep in older people? A randomized cross-over trial. Age Ageing. 2003, 32:164-70. [DOI via Crossref]    [Pubmed]   
40. Asyama K, Yamadera H, Ito T, Suzaki H, Kudo Y et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003; 70:334-41. [DOI via Crossref]   
41. Barrett P, Conway S, Morgan PJ. Digging deep-structure-function relationships in the melatonin receptor family. J Pineal Res. 2003, 35:221-30. [DOI via Crossref]    [Pubmed]   
42. Arendt J. Jetlag. Lancet. 1998; 351:293-4. [DOI via Crossref]   
43. Arendt J. Jet-lag and shift work: (2). Therapeutic use of melatonin. J Royal Soc Med. 1999; 92:402-5. [Pubmed]    [PMC Free Fulltext]   
44. Cardinali DP, Brusco LI, Lloret SP, Furio AM. Melatonin in sleep disorders and jet-lag. Neuroendocrinol Lett. 2002; 23 (Suppl.) 1:9-13.
45. Burch JB, Yost MG, Johnson W, Allen E. Melatonin, sleep, and shift work adaptation. J Occup Environ Med. 2005; 47:893-901. [DOI via Crossref]    [Pubmed]   
46. Arendt J, Shene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005; 9:25-39. [DOI via Crossref]    [Pubmed]   
47. Karbownik M, Lewinski A, Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol. 2001; 33:735-53. [DOI via Crossref]   
48. Karbownik M, Reiter RJ, Burkhardt S, Gitto E, Tan DX et al. Melatonin attenuates estradiol-induced oxidative damage to DNA: relation to cancer prevention. Exp Biol Med. 2001; 226:707-12.
49. Reiter RJ. Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerative diseases. Neuroendocrinol Lett. 2002; 23 (Suppl 2): 9-13. [Pubmed]   
50. Vijayalaxmi, Thomas CR Jr, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002; 2575-601. [Pubmed]   
51. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: The neuroendocrine/circadian melatonin signal. Endocrine. 2005; 27:179-88. [DOI via Crossref]   
52. Mills F, Wu P, Seely D, Guyott G. Melatonin in the treatment of cancer: a systemic review of randomized trials and meta-analysis. J Pineal Res. 2005; 39:360-6. [DOI via Crossref]    [Pubmed]   
53. Sanchez-Barcelo EJ, Cos S, Mediavilla D, Martinez-Campa C, Gonzales A et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res. 2005; 38:217-22. [DOI via Crossref]    [Pubmed]   
54. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M et al. Melatonin inhibition and pinealectomy enhancement of 7, 12-dimethylbenz (a)anthracene-induced mammary tumors in rats. Cancer Res. 1981; 41 (11 Pt 1):4432-6. [Pubmed]   
55. Blask DE, Hill SM, Orstead KM, Massa JS Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7, 12-dimethylbenzanthracene (DMBA)-induced mammary carcinogenesis. J Neural Transm. 1986; 67:125-38. [DOI via Crossref]   
56. Molis TM, Spriggs LL, Jupiter Y, Hill SM. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res. 1995; 18:93-103. [DOI via Crossref]    [Pubmed]   
57. Eck KM, Yuan L, Duffy L, Ram PT, Ayettey S, et al. A sequential treatment regimen with melatonin and all-trans retinoic acid induced apoptosis in MCF-7 tumour cells. Br J Cancer. 1998; 77:2129-37. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
58. Sainz RM, Mayo JC, Rodríguez C, Tan DX, Lopez-Burillo S et al. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Molec Life Sci. 2003; 60:1407-26. [DOI via Crossref]    [Pubmed]   
59. Buyukavci M, Ozdermir O, Buck S, Stout M, Ravindranath Y et al. Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam Clin Pharmacol. 2006; 20:73-9. [DOI via Crossref]    [Pubmed]   
60. Jou MJ, Peng TI, Reiter RJ, Jou BS, Wu HY et al. Visualization of the antioxidant effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res. 2004; 37:55-70. [DOI via Crossref]    [Pubmed]   
61. Sainz RM, Mayo JC, Tan DX, Lopez-Burillo S, Natarajan M et al. Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation. Biochem Biophys Res Commun. 2003; 302:625-34. [DOI via Crossref]   
62. Sauer LA, Dauchy RT, Blask ED. Polyunsaturated fatty acids, melatonin, and cancer prevention. Biochem Pharmacol. 2001; 61:1455-62. [DOI via Crossref]   
63. Hsi LC, Wilson LC, Eling TE. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. J Biol Chem. 2002; 277:40549-56. [DOI via Crossref]    [Pubmed]   
64. Blask DE, Sauer LA, Dauchy R, Holowachuk EW, Ruhoff MS. New actions of melatonin on tumor metabolism and growth. Biol Signals Recept. 1999; 8:49-55. [DOI via Crossref]    [Pubmed]   
65. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 2005; 65:1174-84. [DOI via Crossref]    [Pubmed]   
66. Greider CW, Blackburn EH. Identification of specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985; 43:405-13. [DOI via Crossref]   
67. Bodnar AG, Oullette M, Frolkis M, Hott SF, Chiu CP et al. Extension of life-span by introduction of telomerase into normal cells. Science. 1998; 279:349-52. [DOI via Crossref]    [Pubmed]   
68. Counter CM, Avillon AA, LeFeuvre CE, Stewart NG, Greider CW et al. Telomere shortening associated with chromosomal instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992; 11:1921-9. [Pubmed]    [PMC Free Fulltext]   
69. Leon-Blanco M, Guerrero JM, Reiter RJ, Calvo JR, Pozo D. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res. 2003; 35:204-11. [DOI via Crossref]    [Pubmed]   
70. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004; 37:213-4. [DOI via Crossref]    [Pubmed]   
71. Leon-Blanco MM, Guerrero JM, Reiter RJ, Pozo D. RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line. Cancer Lett. 2004; 216:73-80. [DOI via Crossref]    [Pubmed]   
72. Boldrini L, Gisfredi S, Ursino S, Favianna P, Lucchi M, et al. Expression of endothelin-1 is related to poor prognosis in non-small cell lung cancer. Eur J Cancer 2005; 41:2828-35. [DOI via Crossref]    [Pubmed]   
73. Knowles J, Loizidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol 2005; 3:309-14. [DOI via Crossref]    [Pubmed]   
74. Kilic E, Kilic U, Reiter RJ, Bassetti CL, Hermann DM. Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J Pineal Res 2004; 37:247-251. [DOI via Crossref]    [Pubmed]   
75. Preston-Martin S, Pike MC, ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res. 1990; 50:7415-21. [Pubmed]   
76. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr. 2000; 27:67-73. [DOI via Crossref]    [Pubmed]   
77. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, et al. Genotoxic metabolites of estrodiol in breast: potencial mechanism of estradiol induced carcinogenesis. J Steroid Biochem Molec Biol. 2003; 86:477-86. [DOI via Crossref]   
78. Tan DX, Chen LD, Poeggeler B, Manchester LD, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
79. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. Cell Biochem Biophys. 2001; 34:237-56. [DOI via Crossref]   
80. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Topics Med Chem. 2002; 2:181-97. [DOI via Crossref]   
81. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L et al. The chemistry of melatonin’s interaction with reactive species. J Pineal Res. 2003; 34:1-10. [DOI via Crossref]    [Pubmed]   
82. Rodríguez C, Mayo JC, Sainz RM, Antolin I, Herrera F et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004; 36:1-9. [DOI via Crossref]    [Pubmed]   
83. Tan DX, Poeggeler B, Reiter RJ, Chen LD, Chen S et al. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole. Cancer Lett. 1993; 70:65-71. [DOI via Crossref]   
84. Karbownik M, Reiter RJ. Melatonin protects against oxidative stress caused by detal-aminolevulinic acid: implications for cancer reduction. Cancer Invest. 2002; 20:276-86. [DOI via Crossref]   
85. Reiter RJ. Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerative diseases. Neuroendocrinol Lett. 2002; 23 (Suppl 2):9-13. [Pubmed]   
86. Cos S. Sanchez-Barcelo EJ. Melatonin and mammary pathological growth. Front Neuroendocrinol. 2000; 21:133-70. [DOI via Crossref]    [Pubmed]   
87. Sanchez-Barcelo EJ, Cos S, Fernandez R, Mediavilla MD. Melatonin and mammary cancer: a review. Endocr Relat Cancer. 2003; 10:153-9. [DOI via Crossref]    [Pubmed]   
88. Cos S, Martinez-Campa C, Mediavilla MD, Sanchez-Barcelo EJ. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 2005; 38:136-42. [DOI via Crossref]    [Pubmed]   
89. Landeghem AA, Poortman J, Nabuurs M, Thijssen JG. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985; 45:2900-6. [Pubmed]   
90. Harada N. Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Molec Biol. 1997; 61:175-84. [DOI via Crossref]   
91. Yue W, Wang JP, Hamilton CJ, Dem ers L, Santen RJ. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 1998; 58:927-32. [Pubmed]   
92. Hardeland R, Balzer I, Poeggeler B, Fuhrbert B, Uria H et al. On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicells, photooxidation, and scavenging of free radicals. J Pineal Res. 1995; 18:104-11 [DOI via Crossref]    [Pubmed]   
93. Poeggeler B, Thuermann S, Dose A, Schoenke M, Burkhardt S et al. Melatonin’s unique radical scavenging properties – roles of its functional substituents as revealed by a comparison with its structural analogues. J Pineal Res. 2002; 33:20-30. [DOI via Crossref]    [Pubmed]   
94. Reiter RJ, Tan DX, Manchester LC, Lopez-Burillo S, Sainz RM et al. Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. Adv Exp Med Biol. 2004; 59:539-48.
95. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Progr Neurobiol. 1998; 56:359-84. [DOI via Crossref]   
96. Mayo JC, Rosa RM, Tan DX, Antolin I, Rodriquez C et al, Melatonin and Parkinson’s disease. Endocrine. 2005; 27:169-178. [DOI via Crossref]   
97. Nishida, S. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine. 2550; 27:131-136. [DOI via Crossref]   
98. Halliwell B. Antioxidants and human disease: a general introduction. Nutr Rev. 1997; 55 (1 Pt 2): S44-52. [Pubmed]   
99. Poeggler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res. 1993; 14:151-68. [DOI via Crossref]   
100. Harman D. Aging and oxidative stress. J Int Fed Clin Chem. 1998; 10:24-7. [Pubmed]   
101. Reiter RJ, Guerrero JM, Garcia JJ, Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage, and aging: relation to melatonin. Ann NY Acad Sci. 1998; 854:410-24. [DOI via Crossref]    [Pubmed]   
102. Harman D. Aging: overview. Ann NY Acad Sci. 2001; 928:1-21. [DOI via Crossref]    [Pubmed]   
103. Wu YH, Swaab D. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res 2005; 38:145-152. [DOI via Crossref]    [Pubmed]   
104. Reiter RJ, Tan DX, Maldonado M. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res. 2005; 39:215-16. [DOI via Crossref]    [Pubmed]   
105. Tan DX, Manchester LC, Sainz RM, Mayo JC, Leon J et al. Physiological ischemia/reperfusion phenomena and their relation to endogenous melatonin production: an hypothesis. Endocrine. 2005; 21:149-57. [DOI via Crossref]   
106. Reiter RJ, Tan DX, Kim SJ, Qi W. Melatonin as a pharmacological agent against oxidative damage to lipids and DNA. Proc West Pharmacol Soc. 1998; 41:229-36. [Pubmed]   
107. Chen YH, Xu DX, Wang JP, Wang H, Wei LZ et al. Melatonin protects against lipopolysaccharide-induced intra-uterine fetal death and growth retardation in mice. J Pineal Res. 2006; 40:40-7. [DOI via Crossref]    [Pubmed]   
108. Petrosillo G, Di Venosa N, Pistolese M, Casanova G, Tiravanti E et al. Protective effective of melatonin against mitochondrial dysfunction associated with cardiac ischemia-reperfusion: role of cardiolipin. FASEB J. 2006; 20:269-79. [DOI via Crossref]    [Pubmed]   
109. Reiter RJ, Tan DX, Kim SJ, Manchester LC, Qi W et al. Augmentation of indices of oxidative damage in life-long melatonin-deficient rats. Mech Aging Dev. 1999; 110:157-73. [DOI via Crossref]   
110. Tesoriere L, D’Arpa D, Conti S, Pintaudi AM, Livera MA. Melatonin protects human red blood cells from oxidative hemolysis: new insights into the radical scavenging activity. J Pineal Res. 1999; 27:95-105. [DOI via Crossref]   
111. Okatani Y, Wakatsuki A, Reiter RJ, Miyahara Y. Melatonin reduces oxidative damage of neural lipids and proteins in senescence-accelerated mouse. Neurobiol Aging. 2002; 23:639-44. [DOI via Crossref]   
112. Pappolla MA, Chyan YJ, Poeggeler B, Bozner P, Ghiso J et al. Alzheimer’s beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin. J Pineal Res. 1999; 27:226-9. [DOI via Crossref]    [Pubmed]   
113. Bozner P, Grishko V, La Daux SP, Wilson GL, Chyan Y et al. The amyloid beta protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol. 1997; 56:1356-62. [DOI via Crossref]    [Pubmed]   
114. Onuki J, Almeida EA, Medeiros MH, Di Mascio P. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, quercetin or resveratrol. J Pineal Res. 2005; 38:107-15. [DOI via Crossref]    [Pubmed]   
115. Vijayalaxmi, Reiter RJ, Tan DX, Herman TS, Thomas CR Jr. Melatonin as a radioprotective agent. Int J Radiat Oncol Biol Phys. 2004; 59:639-53. [DOI via Crossref]    [Pubmed]   
116. Benot S, Molinero P, Soutto M, Goberna R, Guerrero JM. Circadian variations in the rat serum total antioxidant status: Correlation with melatonin levels. J Pineal Res. 1998; 25:1-4. [DOI via Crossref]    [Pubmed]   
117. Benot S, Gobena R, Reiter RJ, Garcia-Maurino S, Osuna C et al. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res. 1999; 27:59-64. [DOI via Crossref]    [Pubmed]   
118. Reiter RJ, Manchester LC, Tan DX. Melatonin in walnuts: influence on levels of melatonin and total antioxidant status of blood. Nutrition. 2005; 21:920-4. [DOI via Crossref]    [Pubmed]   
119. Tan DX, Chen LD, Poeggeler G, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
120. Reiter RJ, Tan DX, Gitto E, Sainz RM, Mayo JC et al. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol. 2004; 56:159-170. [Pubmed]   
121. Hardeland R. Antioxidative protection by melatonin. Endocrine. 2005; 27:119-30. [DOI via Crossref]   
122. Tan DX, Manchester LC, Sainz RM, Mayo JC, Leon J et al. Interactions between melatonin and nicotinamide nucleotide: NADH preservation in cells and in cell-free systems by melatonin. J Pineal Res. 2005; 39:185-94. [DOI via Crossref]    [Pubmed]   
123. Tan DX, Manchester LC, Burkhardt S, Sainz RM, Mayo JC et al. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J. 2001; 15:2294-6. [Pubmed]   
124. de Almeida EA, Martinez GR, Klitzke CF, de Medeiros MH, Di Mascio P. Oxidation by melatonin by singlet oxygen produces N1-acetyl-N2-formyl-5-methoxykynuramine. J Pineal Res. 2003; 35:131-7. [DOI via Crossref]    [Pubmed]   
125. Ressmeyer AR, Mayo JC, Zelosko V, Sainz RM, Tan DX et al. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) scavenging of free radicals and prevention of protein destruction. Redox Rep. 2003; 8:205-13. [DOI via Crossref]    [Pubmed]   
126. Silva SO, Rodrigues MR, Carvalho SR, Catalaui LH, Campa A et al. Oxidation of melatonin and its catabolites, N1-acetyl-N2-formyl-5-methoxykynuramine and N-acetyl-5-methoxykynuramine, by activated leukocytes. J Pineal Res 2004; 37:171-5. [DOI via Crossref]    [Pubmed]   
127. Antolin I, Rodriguez C, Sainz RM, Mayo JC, Uria H et al. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J 1996; 10:882-90. [Pubmed]   
128. Rodríguez C, Mayo JC, Sainz RM, Antolin I, Herrera F et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004; 36:1-9. [DOI via Crossref]    [Pubmed]   
129. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res. 2005; 39:99-104. [DOI via Crossref]    [Pubmed]   
130. Urata Y, Honma S, Goto S, Todoroki S, Iida T et al. Melatonin induces gamma-glutamylcysteine synthase mediated by activator protein-1 in human vascular endotelial cells. Free Radic Biol Med. 1999; 27:838-47. [DOI via Crossref]   
131. Winiarska K, Fraczyls T, Malinska D, Drozak J, Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res. 2006; 40:168-76. [DOI via Crossref]    [Pubmed]   
132. Acu-a-Castroviejo A. Escames G, Carazo A, Leon J, Khaldy H et al. Melatonin, mitochondrial homeostasis and mitochondrial related diseases. Curr Top Med chem. 2002; 2:133-51 [DOI via Crossref]   
133. Leon J, Acuna-Castroviejo D, Escames G, Dan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res. 2005; 38:1-9. [DOI via Crossref]    [Pubmed]   
134. Tan DX, Manchester LC, Reiter RJ, Qi W, Kim SJ et al. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res. 1998; 25:184-91. [DOI via Crossref]    [Pubmed]   
135. Dave RH, Hale SL, Kloner RA. The effect of melatonin on hemodynamics, blood flow, and myocardial infarct size in a rabbit model of ischemia-reperfusion. J Cardiovasc Pharmacol Therap. 1998; 3:153-60. [DOI via Crossref]   
136. Lagneux C, Joyeux M, Demenge P, Ribuot C, Godin-Ribuot D. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. Life Sci. 2000; 66:503-9. [DOI via Crossref]   
137. Dobsak P, Siegelova J, Eicher JC, Jancik J, Svacinova H et al. Melatonin protects against ischemia-reperfusion injury and inhibits apoptosis in isolated working rat heart. Pathophysiology. 2003; 9:179-87. [DOI via Crossref]   
138. Reiter RJ, Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. J Cardovasc Res. 2003; 58:10-9. [DOI via Crossref]   
139. Lochner A, Genade S, Davids A, Ytrebus K, Moolman JA. Short- and long-term effects of melatonin on myocardial post ischemic recovery. J Pineal Res. 2006; 20:269-76.
140. Wakatsuki A, Okatani Y, Izumiya C, Ikenove M. Melatonin protects against ischemia and reperfusion-induced oxidative lipid and DNA damage in fetal rat brain. J Pineal Res. 1999; 26:147-52. [DOI via Crossref]    [Pubmed]   
141. Borlongan CV, Yamamoto M, Takei N, Kumazaki M, Ungsuparkorn C et al. Gial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J. 2000; 17:1307-17. [DOI via Crossref]   
142. Cuzzocrea S, Costantino G, Gitto E, Mazzon E, Fulia F et al. Protective effects of melatonin in ischemic brain injury. J Pineal Res. 2000; 29:217-27. [DOI via Crossref]    [Pubmed]   
143. Pei Z, Ho HT, Cheung RT. Pre-treatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci Lett. 2002; 318:141-4. [DOI via Crossref]   
144. Cheung RT. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 2003; 34:153-60. [DOI via Crossref]    [Pubmed]   
145. Kilic E, Kilic U, Yulug B, Hermann DM, Reiter RJ. Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and its suitable as an add-on treatment to tissue-plasminogen activator. J Pineal Res. 2004; 36:171-6. [DOI via Crossref]    [Pubmed]   
146. Gupta S, Kaul CL, Sharma SS Neuroprotective effect of combination of poly (ADF ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rat. Neurol Res. 2004; 26:103-7. [DOI via Crossref]    [Pubmed]   
147. Torii K, Uneyama H, Nishino H, Dondoh T. Melatonin suppresses cerebral edema caused by middle cerebral artery occlusion/reperfusion in rats assessed by magnetic resonance imaging. J Pineal Res. 2004; 36:18-24. [DOI via Crossref]    [Pubmed]   
148. Lee EJ, Lee MY, Chen HY, Hsu YS, Wu TS et al. Melatonin attenuates gray and white matter damage in mouse model of transient focal cerebral ischemia. J Pineal Res. 2005; 38:42-53. [DOI via Crossref]    [Pubmed]   
149. Guerrero JM, Reiter RJ, Ortiz GG, Pablos MI, Sewerynek E et al. Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meriones unguiculatus). J Pineal Res. 1997; 23:24-31. [DOI via Crossref]    [Pubmed]   
150. El-Abhar HS, Shaalan M, Barakat M, El-Denshary ES. Effect of melatonin nifedipine on some antioxidant enzymes and different energy fuels in the blood and brain of global ischemic rats. J Pineal Res 2002; 33:87-94. [DOI via Crossref]    [Pubmed]   
151. Reiter RJ, Sainz RM, Lopez-Burillo S, Mayo JC, Manchester LC et al. Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. Ann NY Acad Aci. 2003; 993:35-47. [DOI via Crossref]   
152. Yamaguchi H. Illustration of dynamic changes in Alzheimer pathology: from mild impairment to terminal stage. Neuropathology. 2005; 25:285-7. [DOI via Crossref]    [Pubmed]   
153. Polick J, Corey-Bloom J. Alzheimer’s disease and P300: review and evaluation of task and modality. Curr Alzheimer Res. 2005; 2:515-25. [DOI via Crossref]   
154. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002; 298:789-91. [DOI via Crossref]    [Pubmed]   

This Article Cited By the following articles

Melatonin: a “Higgs boson” in human reproduction
Gynecol Endocrinol 2015; 31(2): 92.

1
 
Melatonin reduces oxidative stress and restores mitochondrial function in the liver of rats exposed to chemotherapeutics
J. Exp. Zool. 2015; (): n/a.

2
 
Anticonvulsant efficacy of melatonin in an experimental model of hyperthermic febrile seizures
Epilepsy Research 2015; 118(): 49.

3
 
Melatonin: a “Higgs boson” in human reproduction
Gynecol Endocrinol 2014; (): 1.

4
 
Glucose: A vital toxin and potential utility of melatonin in protecting against the diabetic state
Molecular and Cellular Endocrinology 2012; 349(2): 128.

5
 
The role of melatonin in acute myocardial infarction
Frontiers in Bioscience 2012; 17(7): 2433.

6
 
Reactive nitrogen species; devastating intracellular players and melatonin as a defender
J Exp Integr Med 2011; (): 63.

7
 
Melatonin ameliorates necrotizing enterocolitis in a neonatal rat model
Journal of Pediatric Surgery 2011; 46(11): 2101.

8
 
Efficacy of melatonin, mercaptoethylguanidine and 1400W in doxorubicin- and trastuzumab-induced cardiotoxicity
Journal of Pineal Research 2011; 50(1): 89-96.

9
 
Effects of Combined Use of Trospium Chloride and Melatonin on In Vitro Contractility of Rat Urinary Bladder
Urology 2010; 75(4): 873.

10
 
Melatonin: Action as antioxidant and potential applications in human disease and aging
Toxicology 2010; 278(1): 55.

11
 
Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats
Cell Biochemistry and Function 2010; 28(5): 426-433.

12
 
The use of melatonin to combat mustard toxicity. REVIEW.
Neuro endocrinology letters 2008; 29(5): 614-9.

13
 
Establishing the Use of Melatonin as an Adjuvant Therapeutic Against Paraquat-Induced Lung Toxicity in Rats
Experimental Biology and Medicine 2008; 233(9): 1133-1141.

14
 
Melatonin as an antibiotic: new insights into the actions of this ubiquitous molecule
Journal of Pineal Research 2008; 44(2): 222-226.

15
 
Epigenetic regulation: a new research area for melatonin?
Journal of Pineal Research 2007; 0(0): 071027215641001-???.

16
 
Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard
Toxicology Letters 2007; 173(2): 124-131.

17
 

How to Cite this Article
Pubmed Style

REITER RJ, GULTEKIN F, FLORES LJ, TERRON MP, TAN D. [MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH]. TAF Prev Med Bull. 2006; 5(2): 131-158. Turkish. doi:10.5455/pmb.20060502131



Web Style

REITER RJ, GULTEKIN F, FLORES LJ, TERRON MP, TAN D. [MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH]. www.scopemed.org/?mno=175 [Access: May 27, 2017]. Turkish. doi:10.5455/pmb.20060502131



AMA (American Medical Association) Style

REITER RJ, GULTEKIN F, FLORES LJ, TERRON MP, TAN D. [MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH]. TAF Prev Med Bull. 2006; 5(2): 131-158. Turkish. doi:10.5455/pmb.20060502131



Vancouver/ICMJE Style

REITER RJ, GULTEKIN F, FLORES LJ, TERRON MP, TAN D. [MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH]. TAF Prev Med Bull. (2006), [cited May 27, 2017]; 5(2): 131-158. Turkish. doi:10.5455/pmb.20060502131



Harvard Style

REITER, R. J., GULTEKIN, F. ., FLORES, L. J., TERRON, M. P. . & TAN, D. . (2006) [MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH]. TAF Prev Med Bull, 5 (2), 131-158. Turkish. doi:10.5455/pmb.20060502131



Turabian Style

REITER, Russel J, Fatih GULTEKIN, Luis J FLORES, Ma Pilar TERRON, and Dun-Xian TAN. 2006. [MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH]. TAF Preventive Medicine Bulletin, 5 (2), 131-158. Turkish. doi:10.5455/pmb.20060502131



Chicago Style

REITER, Russel J, Fatih GULTEKIN, Luis J FLORES, Ma Pilar TERRON, and Dun-Xian TAN. "[MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH]." TAF Preventive Medicine Bulletin 5 (2006), 131-158. Turkish. doi:10.5455/pmb.20060502131



MLA (The Modern Language Association) Style

REITER, Russel J, Fatih GULTEKIN, Luis J FLORES, Ma Pilar TERRON, and Dun-Xian TAN. "[MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH]." TAF Preventive Medicine Bulletin 5.2 (2006), 131-158. Print.Turkish. doi:10.5455/pmb.20060502131



APA (American Psychological Association) Style

REITER, R. J., GULTEKIN, F. ., FLORES, L. J., TERRON, M. P. . & TAN, D. . (2006) [MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH]. TAF Preventive Medicine Bulletin, 5 (2), 131-158. Turkish. doi:10.5455/pmb.20060502131



AUTHOR LOGIN

REVIEWER LOGIN

Indexed In

EBSCOhost
ScopeMed
TBTAK Turkish Medical Index
AkademikDizin
IndexScholar
Scopus
CAB Abstracts
Global Health Database
DOAJ
IndexCopernicus
Turk Medline (Pleksus)
Google Scholar




The articles in TAF Preventive Medicine Bulletin are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.